|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
4 May 2015 |
|
Main ID: |
NCT01492127 |
|
Date of registration:
|
12/12/2011 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment
|
|
Scientific title:
|
Evolution of Plasma Proteasome Levels Following Curative Treatment of Hepatocellular Carcinoma in Cirrhotic Patients |
|
Date of first enrolment:
|
December 2011 |
|
Target sample size:
|
64 |
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT01492127 |
|
Study type:
|
Interventional |
|
Study design:
|
Intervention Model: Single Group Assignment, Masking: Open Label
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
France
| | | | | | | |
|
Contacts
|
|
Name:
|
Natalie Funakoshi |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University Hospital, Montpellier |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Cirrhotic patients with hepatocellular carcinoma proven by histological examination
of a biopsy specimen, eligible for curative treatment (radiofrequency, surgical
resection, liver transplantation)
- Patient able to give informed consent
- Patient with Social Security coverage
Exclusion Criteria:
- Secondary liver tumors
- Non hepatocellular carcinoma primary liver tumor
- Hepatocellular carcinoma without cirrhosis
- Patients with hepatocellular carcinoma and cirrhosis not eligible for curative
treatment
- Prisoners
- Adults under guardianship or curatorship
- Pregnancy
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Cirrhosis
|
|
Hepatocellular Carcinoma
|
|
Intervention(s)
|
|
Biological: Blood test
|
|
Primary Outcome(s)
|
|
Variation of plasma proteasome
[Time Frame: 3 months afterwards]
|
|
Secondary Outcome(s)
|
|
Variation of plasma proteasome
[Time Frame: 6, 9 and 12 months]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|